Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01856374
Other study ID # 1-2010-0052
Secondary ID
Status Completed
Phase Phase 4
First received May 9, 2013
Last updated July 25, 2016
Start date August 2011
Est. completion date October 2014

Study information

Verified date July 2016
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry of Food and Drug Safety
Study type Interventional

Clinical Trial Summary

This study is a prospective open-labeled, randomized study to compare the neointimal coverage at 3 months and 12 months and its serial changes between 3 months and 12 months according to the implanted DES and evaluate the serial changes in the proximal portions of 3 epicardial coronary artery and left main artery including the assessment of fibrous cap thickness and lipid pool for vulnerable plaques by OCT. In addition, the investigators will compare the changes such as plaques and neointimal coverage from serial OCT follow-up according to the different statin strategy.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date October 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Patient is = 20 years old

- Patients with typical angina who are considered for coronary revascularization.

- Multi-vessel diseases: more than 2 significant coronary de novo lesions (> 70% by quantitative angiographic analysis); one of the target lesions is the most significant tight stenotic lesion causing the ischemic symptom and requiring the immediate revascularization but the others are significant but non-tight lesions to be delayed or observed for 3 months and not requiring immediate PCI for the complete revascularization of all coronary arteries.

Exclusion Criteria:

- ST-elevation MI

- Cardiogenic shock or hemodynamically unstable status

- Lesions requiring the immediate complete revascularization of all coronary stenotic lesions

- Contraindication to anti-platelet agents

- Treated with any DES within 6 months at other vessel

- Creatinine level = 2.0 mg/dL or ESRD

- Severe hepatic dysfunction (3 times normal reference values)

- Pregnant women or women with potential childbearing

- Life expectancy 1 year

- Complex lesion morphologies (bifurcation lesions treated with 2-stent techniques, untreated significant unprotected left main diseases, chronic total occlusion, in-stent restenosis, and vein graft lesion)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)
Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)
Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
Drug:
Pravastatin 20mg
2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
Atorvastatin 40mg
2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.

Locations

Country Name City State
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary neointimal coverage according to the implanted DES; Xience vs. Cypher Neointimal coverage means percentage of uncovered struts on OCT. The percentages of uncovered struts were compared between EES and SES. up to 12month after stent implantation No